Laura Hayes | Attorney | Hagens Berman

Ms. Hayes is involved in class-action lawsuits against pharmaceutical companies and is committed to the vigorous prosecution of antitrust cases.

Current Role

Of Counsel, Hagens Berman Sobol Shapiro LLP

Recent Cases

Experience

Member of the team responsible for $94 million settlement on behalf of direct purchaser class in In re Celebrex (Celecoxib) Antitrust Litigation, 2:13-cv-361, E.D. Va., ECF Nos. 64, 455, and the $120 million settlement (motion for preliminary approval pending) in In re Loestrin 24 Fe Antitrust Litigation, 1:13-md-02472, D.R.I., ECF Nos. 10, 1050
Prior to joining Hagens Berman, was an associate at Gargiulo Rudnick LLP, where she litigated Medicaid and Medicare fraud cases, also has years of work experience doing contract work on a variety of complex litigations
Following law school, served as a clerk for the Connecticut Judicial Branch, addressed novel pre-emption and spoliation of evidence questions
A graduate of Boston University School of Law, where she acted as articles editor for the Journal of Science and Technology Law
Recieved her Bachelor of Science degree from Boston University with a concentration in journalism

Personal Insight

Laura spends her free time in a variety of quixotic endeavors including dog sledding, trying to learn languages (currently Icelandic), proselytizing on the virtues of a certain sci-fi show, and trying to explain to non-lawyers why antitrust law is so important.

Related Cases

CASES IN THE NEWS

All Cases

Intuniv Antitrust

Hagens Berman filed a lawsuit against drug makers Shire and Actavis alleging the two conspired to delay the availability of affordable generic versions of Shire’s ADHD drug, Intuniv.

Amitiza Antitrust

Hagens Berman filed an antitrust lawsuit against Takeda and Par on behalf of a proposed class of direct purchasers of Amitiza and its generic equivalents.

Xyrem Antitrust Litigation

Hagens Berman filed a lawsuit that alleges Jazz Pharmaceuticals Inc. engaged in anticompetitive behavior with the intention of delaying generic competition for its brand drug Xyrem.

Revlimid Antitrust

Hagens Berman filed an amended complaint on behalf of a direct purchaser alleging that Celgene Corporation and its parent Bristol-Myers Squibb Company engaged in extensive anticompetitive conduct to delay generic competition for cancer drug Revlimid and its predecessor Thalomid.